12/20
08:37 am
imnm
Immunome Chairman Acquires 5.8% More Stock [Yahoo! Finance]
Low
Report
Immunome Chairman Acquires 5.8% More Stock [Yahoo! Finance]
12/17
02:49 pm
imnm
Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat [Seeking Alpha]
Medium
Report
Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat [Seeking Alpha]
12/17
04:05 am
imnm
Immunome prices $400M stock offering at $21.50 a share [Seeking Alpha]
High
Report
Immunome prices $400M stock offering at $21.50 a share [Seeking Alpha]
12/17
12:43 am
imnm
Stock Market Today: Russell 2000, Nasdaq Saddle Tech Pullback Ahead of Big Week of Data [Yahoo! Finance]
High
Report
Stock Market Today: Russell 2000, Nasdaq Saddle Tech Pullback Ahead of Big Week of Data [Yahoo! Finance]
12/16
08:29 pm
imnm
Immunome Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]
High
Report
Immunome Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]
12/16
08:16 pm
imnm
Immunome Announces Pricing of Public Offering of Common Stock
High
Report
Immunome Announces Pricing of Public Offering of Common Stock
12/16
10:09 am
imnm
Immunome (NASDAQ:IMNM) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
Low
Report
Immunome (NASDAQ:IMNM) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
12/16
09:32 am
imnm
Immunome (NASDAQ:IMNM) had its price target raised by analysts at Evercore ISI from $18.00 to $40.00. They now have an "outperform" rating on the stock.
Medium
Report
Immunome (NASDAQ:IMNM) had its price target raised by analysts at Evercore ISI from $18.00 to $40.00. They now have an "outperform" rating on the stock.
12/16
08:43 am
imnm
Immunome (NASDAQ:IMNM) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Immunome (NASDAQ:IMNM) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/16
08:36 am
imnm
Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application [Yahoo! Finance]
Medium
Report
Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application [Yahoo! Finance]
12/15
06:20 pm
imnm
Why Immunome Stock Surged Today [Yahoo! Finance]
Medium
Report
Why Immunome Stock Surged Today [Yahoo! Finance]
12/15
06:00 pm
imnm
Immunome (NASDAQ:IMNM) was given a new $40.00 price target on by analysts at Leerink Partners.
Medium
Report
Immunome (NASDAQ:IMNM) was given a new $40.00 price target on by analysts at Leerink Partners.
12/15
04:45 pm
imnm
Immunome Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Immunome Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
12/15
04:01 pm
imnm
Immunome Announces Proposed Public Offering of Common Stock
Medium
Report
Immunome Announces Proposed Public Offering of Common Stock
12/15
12:49 pm
imnm
Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more [CNBC]
Medium
Report
Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more [CNBC]
12/15
08:10 am
imnm
Immunome Says Phase 3 Trial for Varegacestat in Patients with Desmoid Tumors Meets Primary and Secondary Endpoints [Yahoo! Finance]
Medium
Report
Immunome Says Phase 3 Trial for Varegacestat in Patients with Desmoid Tumors Meets Primary and Secondary Endpoints [Yahoo! Finance]
12/15
07:50 am
imnm
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors [Yahoo! Finance]
High
Report
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors [Yahoo! Finance]
12/15
07:30 am
imnm
Immunome's experimental drug meets main goal in late-stage study [Yahoo! Finance]
High
Report
Immunome's experimental drug meets main goal in late-stage study [Yahoo! Finance]
12/15
07:00 am
imnm
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
Medium
Report
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
12/14
04:00 pm
imnm
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
High
Report
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
12/4
04:05 pm
imnm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1
08:45 am
imnm
Immunome (NASDAQ:IMNM) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $36.00 price target on the stock.
Low
Report
Immunome (NASDAQ:IMNM) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $36.00 price target on the stock.
11/25
08:45 am
imnm
Immunome to Present at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Immunome to Present at Upcoming Investor Conferences [Yahoo! Finance]
11/25
08:00 am
imnm
Immunome to Present at Upcoming Investor Conferences
Low
Report
Immunome to Present at Upcoming Investor Conferences
11/22
02:11 am
imnm
Low
Report